|
Match
|
Document |
Document Title |
|
|
US20110293723 |
SYNTHETIC NANOCARRIER COMBINATION VACCINES
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are... |
|
|
US20150174229 |
INACTIVATED MYCOBACTERIA FOR ORAL USE IN THE PREVENTION OF TUBERCULOSIS
An inactivated mycobacteria for oral use in the prevention of tuberculosis, which are administered using a multi-dose regimen and with a reduced time interval between doses, such as to induce a... |
|
|
US20110189208 |
TB VACCINE
The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections. |
|
|
US20140356397 |
Immunogenic Treatment Of Cancer
The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously,... |
|
|
US20110064723 |
Formulation for room temperature stabilization of a live attenuated bacterial vaccine
This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are... |
|
|
US20110110979 |
METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES
The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus... |
|
|
US20110052637 |
PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS VACCINES
The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as vaccines. |
|
|
US20140322268 |
SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS
Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5,... |
|
|
US20130337011 |
RECOMBINANT MYCOBCTERIUM AS A VACCINE
The invention relates to a recombinant Mycobacterium cell for use as a vaccine. |
|
|
US20110117119 |
NOVEL COMPOSITIONS AND METHODS
The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c... |
|
|
US20140178423 |
NOVEL COMPOSITIONS AND METHODS
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c... |
|
|
US20110223200 |
NOVEL COMPOSITIONS AND METHODS
The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c... |
|
|
US20120321656 |
OLIGOPEPTIDES AND THEIR USE FOR TREATING INFECTIOUS DISEASES
The invention discloses identification, method of making and therapeutic use of synthetic oligopeptides for the treatment of infectious diseases, in particular tuberculosis. The oligopeptides are... |
|
|
US20110311478 |
Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become... |
|
|
US20130058997 |
VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant... |
|
|
US20120003268 |
SYNERGISTIC COMBINATION AND METHOD THEREOF
A method for the treatment of myeloma and thymoma by administering a therapeutically effective dose of Mycobacterium indicus pranii with Cyclophosphamide. This disclosure generally relates to the... |
|
|
US20110250224 |
ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES
The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis... |
|
|
US20110117133 |
Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease
A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or... |
|
|
US20110206712 |
TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c... |
|
|
US20130052229 |
COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS
Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one... |
|
|
US20140356395 |
METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE
This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in... |
|
|
US20150224188 |
USE OF MEMBRANE VESICLE-BASED VACCINE AGAINST M. TUBERCULOSIS
Provided are compositions comprising a plurality of isolated mycobacterium membrane vesicles, and methods of use thereof, and methods of improving the efficacy of immunizations. Throughout this... |
|
|
US20110027349 |
POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM
A vaccine is provided wherein a polypeptide or combination of peptides from M. tuberculosis is administered to a subject to elicit an immune response. The polypeptide vaccine is administered as... |
|
|
US20130330375 |
Therapeutic Cancer Vaccine
The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer... |
|
|
US20130045228 |
VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS
The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer... |
|
|
US20150246080 |
TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH ISOLATED MYCOBACTERIUM
The present invention relates to treatment or prevention of post-traumatic stress disorder (PTSD). In particular, the present invention relates to an isolated Mycobacterium, for use in the... |
|
|
US20110081382 |
TREATMENT AND PREVENTION OF TUBERCULOSIS
The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related... |
|
|
US20140227324 |
USE OF AN IL12 RECEPTOR-BETA 1 SPLICE VARIANT TO DIAGNOSE ACTIVE TUBERCULOSIS
The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M.... |
|
|
US20120189662 |
Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle... |
|
|
US20120141533 |
MYCOBACTERIAL MUTANTS INDUCING IL-12
Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines... |
|
|
US20100310585 |
THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT
Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at... |
|
|
US20130101623 |
ATTENUATED MYCOBACTERIAL STRAIN AS NOVEL VACCINE AGAINST TUBERCULOSIS
The present invention provides a novel attenuated vaccine for tuberculosis. Furthermore, when used as a subcutaneous vaccine, the present invention induces a higher level of protection than the... |
|
|
US20150258187 |
Tuberculosis Vaccine And Method Of Using Same
Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is than formulated for... |
|
|
US20130273110 |
Tuberculosis Vaccine And Method Of Using Same
Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is than formulated for... |
|
|
US20130142825 |
METHOD OF PREVENTING AND TREATING INFLAMMATORY DISEASES AND DISORDERS WITH ABSCISIC ACID
The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide... |
|
|
US20110135578 |
MYCOBACTERIAL INFECTIONS
The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's... |
|
|
US20110262361 |
EFFECTIVE NEW DRUG TARGET FOR THE TREATMENT OF TUBERCULOSIS
The present invention allows a screening method for identifying novel drugs for the treatment of tuberculosis as well as a diagnostic method for identifying clinical strains that are resistant to... |
|
|
US20110104180 |
NEW VACCINE FOR THE TREATMENT OF MYCOBACTERIUM RELATED DISORDERS
The invention relates to genes and proteins involved in the sporulation of Mycobacteria and the use thereof in the technical fields of immunology and medicine. A vaccine comprising spore forming... |
|
|
US20150202276 |
METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS
Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional... |
|
|
US20120244182 |
USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance... |
|
|
US20110311477 |
Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies
The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become... |
|
|
US20150071873 |
Cancer Treatment by Immunotherapy With BCG or Antigenically Related Non-Pathogenic Mycobacteria
A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a Mycobacterium bovis bacillus Calmette-Guerin (BCG), an antigenically related... |
|
|
US20140147468 |
LPRG AS A CHAPERONE OF IMMUNE ADJUVANTS
An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to... |
|
|
US20130149376 |
VACCINE COMPOSITION BASED ON STICHOLYSIN ENCAPSULATED INTO LIPOSOMES
The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into... |
|
|
US20150140039 |
IMMUNOLOGICAL MARKERS FOR ADJUVANT THERAPY IN MELANOMA
The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more SNPs in particular... |
|
|
US20120128720 |
MYCOBACTERIUM MUTANTS FOR VACCINES WITH IMPROVED PROTECTIVE EFFICACY
Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is Mycobacterium bovis Bacille Calmette-Guerin (M. bovis BCG). In the present invention, mutation of... |
|
|
US20120045476 |
LIVE ATTENUATED MYCOPLASMA STRAINS
The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase,... |
|
|
US20130022638 |
Tuberculosis Vaccine
The present invention relates to an isolated microorganism belonging to the genus Mycobacterium, characterized in that it comprises inactivating the gene Rv0757 that confers a PhoP− phenotype and... |
|
|
US20120039925 |
TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION
The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by... |
|
|
US20110243992 |
METHODS OF ENHANCING THE IMMUNOGENICITY OF MYCOBACTERIA AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUBERCULOSIS, AND FIBROSING LUNG DISEASES
Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic... |